Shanghai Junshi Biosciences Adjusts R&D Funding Strategy

An announcement from Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ) is now available.

Shanghai Junshi Biosciences Co., Ltd. announced adjustments to the allocation of proceeds from its 2022 issuance of A shares, aiming to enhance the efficiency of its R&D projects. The company plans to increase investment in certain sub-projects, such as JS207 and JS107, while reducing funding for others, including JS001 and JS004, reflecting strategic shifts in its drug development priorities.

The most recent analyst rating on (HK:1877) stock is a Hold with a HK$12.00 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.

More about Shanghai Junshi Biosciences Co., Ltd. Class H

Shanghai Junshi Biosciences Co., Ltd. is a biotechnology company based in China, focusing on the research and development of innovative drugs. The company operates in the pharmaceutical industry, primarily targeting advanced solid tumors and other serious health conditions through its R&D projects.

Average Trading Volume: 2,963,762

Technical Sentiment Signal: Buy

Current Market Cap: HK$29.72B

See more insights into 1877 stock on TipRanks’ Stock Analysis page.